SCHEMBL10098488

SCHEMBL10098488

CN1CCN(CC(N)CCC(N)=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
ALOX15 P16050 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
PAOX Q6QHF9 1/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 2/20 0.37
TSHR P16473 2/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP2D6 P10635 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16103625 1.00 KMT2A (0.41) KMT2AALOX15BLMPMP22L3MBTL1
SCHEMBL10098465 0.82 L3MBTL1 (0.55) KMT2AALOX15BLMPMP22L3MBTL1
SCHEMBL16103720 0.82 L3MBTL1 (0.55) KMT2AALOX15BLMPMP22L3MBTL1
SCHEMBL10098459 0.79 KDM4E (0.52) KMT2AALOX15BLMPMP22L3MBTL1
SCHEMBL16103709 0.79 KDM4E (0.52) KMT2AALOX15BLMPMP22L3MBTL1
SCHEMBL2852219 0.75 L3MBTL1 (0.65) L3MBTL1PAOXPOLBMAPTTSHR
SCHEMBL15876288 0.74 GAA (0.40) KMT2APAOXPOLBMAPTTSHR
Hydrochloric Acid SCHEMBL7430675 0.74 L3MBTL1 (0.63) L3MBTL1PAOXPOLBMAPTTSHR
SCHEMBL5386430 0.74 GAA (0.42) KMT2APAOXPOLBMAPTTSHR
SCHEMBL2091283 0.74 PAOX (0.60) L3MBTL1PAOXTSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841257-B2 Inhibitors of STAT3 and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-09-23 US disclosed
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-09 US disclosed
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-09 US disclosed
WO-2010118309-A2 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF STAT3, JAK2, STAT6 KMT2A 2506/4885ALOX15 2409/4885BLM 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.